NO20042730L - Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft - Google Patents

Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft

Info

Publication number
NO20042730L
NO20042730L NO20042730A NO20042730A NO20042730L NO 20042730 L NO20042730 L NO 20042730L NO 20042730 A NO20042730 A NO 20042730A NO 20042730 A NO20042730 A NO 20042730A NO 20042730 L NO20042730 L NO 20042730L
Authority
NO
Norway
Prior art keywords
preparation
combination
cancer drug
antineoplastic agents
protein transferase
Prior art date
Application number
NO20042730A
Other languages
English (en)
Norwegian (no)
Inventor
David L Cutler
Michael L Meyers
Charles Baum
Sara L Zaknoen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20042730L publication Critical patent/NO20042730L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20042730A 2001-11-30 2004-06-29 Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft NO20042730L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
NO20042730L true NO20042730L (no) 2004-06-29

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042730A NO20042730L (no) 2001-11-30 2004-06-29 Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN1617755A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533838A (ja) * 2002-07-24 2005-11-10 ノバルティス アクチエンゲゼルシャフト 未分化甲状腺癌を処置するための4−(4−メチルピペラジン−1−イルメチル)−n−[4−メチル−3−(4−ピリジン−3−イル)ピリミジン−2−イルアミノ]フェニル]−ベンズアミド
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
JP2007525507A (ja) * 2004-02-26 2007-09-06 ザ ペン ステイト リサーチ ファンデーション オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
WO2008051531A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Discontinuous methods of treating cancer
WO2008067144A2 (en) * 2006-11-28 2008-06-05 Smithkline Beecham (Cork) Limited Cancer treatment method
US20230390197A1 (en) * 2020-10-27 2023-12-07 Wisconsin Alumni Research Foundation Modular dendron micelles for combination immunotherapy
AU2023376684A1 (en) 2022-11-09 2025-06-19 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1041985T3 (da) * 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en) * 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
CA2397448A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
ZA200403737B (en) 2005-05-23
WO2003047697A3 (en) 2003-10-30
MXPA04005207A (es) 2004-08-19
US20060183765A1 (en) 2006-08-17
CA2468839A1 (en) 2003-06-12
JP2005511663A (ja) 2005-04-28
HUP0402401A2 (hu) 2005-03-29
EP1448268A2 (en) 2004-08-25
CN101181269A (zh) 2008-05-21
NZ532562A (en) 2007-02-23
US20030185831A1 (en) 2003-10-02
CN1617755A (zh) 2005-05-18
BR0214564A (pt) 2004-11-09

Similar Documents

Publication Publication Date Title
DE60209145D1 (de) Pharmazeutische formulierungen mit platinderivaten
EE04579B1 (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
NO20030627L (no) Hydrogel-drevet medikament doseringsform
DE69925133D1 (de) Pyrrolobenzodiazepine
ATE395053T1 (de) Pharmazeutische salze von 1-phenyl-3- dimethylamino-propan-verbindungen
NO20003219L (no) Oral farmasøytisk doseringsform med pulsert frigivningsvirkning
ID28427A (id) Benda penyerap cairan tubuh sekali pakai
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
ITTO20010008A0 (it) Formulazione farmaceutica
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
NO20034439L (no) Benzamidinderivater
DE60127002D1 (de) Pharmazeutische zusammensetzung
EE05020B1 (et) Glburiidi ravimkoostis
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
EP1411904A4 (en) PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE
NO20042730L (no) Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft
EE05333B1 (et) Makroliidhendite konjugaadid p?letikuvastaste henditega ja nende kasutamine
EE05543B1 (et) Tuumorinekroositeguri antagonisti kasutamine endometrioosi raviks ette n„htud farmatseutilise kompositsiooni valmistamiseks
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
DE60129238D1 (de) Pharmazeutische zusammensetzung
SI1475379T1 (sl) Uporaba derivatov skopinskega estra za pripravo zdravil
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application